SK138199A3 - Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus - Google Patents

Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus Download PDF

Info

Publication number
SK138199A3
SK138199A3 SK1381-99A SK138199A SK138199A3 SK 138199 A3 SK138199 A3 SK 138199A3 SK 138199 A SK138199 A SK 138199A SK 138199 A3 SK138199 A3 SK 138199A3
Authority
SK
Slovakia
Prior art keywords
hpv
concentration
seq
protein
human papillomavirus
Prior art date
Application number
SK1381-99A
Other languages
English (en)
Slovak (sk)
Inventor
Gautum Sanyal
David B Volkin
Li Shi
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709351.2A external-priority patent/GB9709351D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SK138199A3 publication Critical patent/SK138199A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
SK1381-99A 1997-04-08 1998-04-07 Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus SK138199A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4280897P 1997-04-08 1997-04-08
GBGB9709351.2A GB9709351D0 (en) 1997-05-07 1997-05-07 Stabilized human papillomavirus formulations
PCT/US1998/006825 WO1998044944A2 (en) 1997-04-08 1998-04-07 Stabilized human papillomavirus formulations

Publications (1)

Publication Number Publication Date
SK138199A3 true SK138199A3 (en) 2000-06-12

Family

ID=26311501

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1381-99A SK138199A3 (en) 1997-04-08 1998-04-07 Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus

Country Status (18)

Country Link
EP (1) EP0973546B1 (de)
JP (1) JP4598201B2 (de)
KR (1) KR20010006169A (de)
CN (1) CN1259051A (de)
AT (1) ATE261734T1 (de)
AU (1) AU739829B2 (de)
CA (1) CA2286294A1 (de)
DE (1) DE69822452T2 (de)
DK (1) DK0973546T3 (de)
EE (1) EE9900612A (de)
ES (1) ES2216280T3 (de)
IL (1) IL132201A0 (de)
NO (1) NO994879L (de)
NZ (1) NZ500028A (de)
PL (1) PL336715A1 (de)
PT (1) PT973546E (de)
SK (1) SK138199A3 (de)
WO (1) WO1998044944A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
SI1150712T1 (sl) 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
KR101515489B1 (ko) 2006-09-29 2015-04-30 다케다 백신즈 인코포레이티드 노로바이러스 백신 제제
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
WO2009092113A2 (en) * 2008-01-19 2009-07-23 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the delivery of vaccines to disrupted epithelium
SI2651436T1 (sl) * 2010-12-14 2016-07-29 Glaxosmithkline Biologicals S.A. Mikrobakterijski antigenski sestavek
CN102085354A (zh) * 2010-12-30 2011-06-08 重庆大学 一种治疗人乳头瘤病毒16型引发的肿瘤的多肽药物
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
CN105039358B (zh) * 2013-12-03 2020-02-28 北京康乐卫士生物技术股份有限公司 58型重组人乳头瘤病毒病毒样颗粒及其制备方法
AU2015313756A1 (en) * 2014-09-11 2017-03-09 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106399329B (zh) * 2015-08-12 2021-06-11 北京康乐卫士生物技术股份有限公司 33型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN106701797B (zh) * 2015-08-12 2021-06-15 北京康乐卫士生物技术股份有限公司 31型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN108201623A (zh) * 2016-12-19 2018-06-26 无锡鑫连鑫生物医药科技有限公司 人乳头瘤病毒重组四价疫苗、其制备方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
EP0732936B1 (de) * 1993-12-09 2000-03-29 Heinrich Exner Adjuvans für antigene, verfahren zur herstellung und verwendung
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein

Also Published As

Publication number Publication date
KR20010006169A (ko) 2001-01-26
JP4598201B2 (ja) 2010-12-15
PL336715A1 (en) 2000-07-03
EE9900612A (et) 2000-08-15
DE69822452T2 (de) 2006-04-20
EP0973546B1 (de) 2004-03-17
WO1998044944A2 (en) 1998-10-15
JP2001519814A (ja) 2001-10-23
PT973546E (pt) 2004-06-30
ATE261734T1 (de) 2004-04-15
AU6953398A (en) 1998-10-30
IL132201A0 (en) 2001-03-19
DE69822452D1 (de) 2004-04-22
AU739829B2 (en) 2001-10-18
ES2216280T3 (es) 2004-10-16
DK0973546T3 (da) 2004-06-28
WO1998044944A3 (en) 1998-12-30
NO994879L (no) 1999-12-07
EP0973546A2 (de) 2000-01-26
CN1259051A (zh) 2000-07-05
NZ500028A (en) 2001-08-31
NO994879D0 (no) 1999-10-07
CA2286294A1 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
US6159729A (en) Synthetic HPV6/11 hybrid L1 DNA encoding human papillomavirus type 11 L1 protein
CA2189882C (en) Papillomavirus vaccines
KR101203403B1 (ko) 효모에서 ｈｐｖ 52 ｌ1의 최적화된 발현
SK138199A3 (en) Human papillomavirus antigen formulation and method for stabilizing a population of virus-like purified particles, derived from protein l1 or protein l1 and l2 of human papillomavirus
US5821087A (en) Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
EP0817851B1 (de) Für menschliches papillomavirus stamm 18 kodierende dns
HUT77559A (hu) Tisztított papillomavírus-proteinek
US5888516A (en) Recombinant papillomavirus vaccines
US6358744B1 (en) Stabilized human papillomavirus formulations
CZ356799A3 (cs) Prostředek obsahující antigen lidského papilomaviru